Substance / Medication

Scopolamine

Overview

Active Ingredient
scopolamine
RxNorm CUI
9601

Indications

Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.

Labeler: Rhodes Pharmaceuticals L.P.Updated: 2026-02-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Scopolamine transdermal system is contraindicated in patients with: Warnings and Precautions (5.1) [see] angle closure glaucoma. Adverse Reactions (6.2) Description (11) [see,] hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or deliv

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
1
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The effect of scopolamine on memory and attention: a systematic review and meta-analysis.
Miravalles Cerena, Cannon Dara M, Hallahan Brian · Eur Psychiatry · 2025
PMID: 40197394Meta-AnalysisFull text (PMC)
A Systematic Review of the Role of Gummosin in Improving Memory in the Scopolamine Impaired Memory Model.
Asadi Rizi A, Amjad L, Shahrani M et al. · Arch Razi Inst · 2024
PMID: 39463714Meta-AnalysisFull text (PMC)
Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis.
Lanpher Nick W, Schnittka Emma M, Haggag Akram · Int Urogynecol J · 2023
PMID: 36719449Meta-Analysis
Scopolamine Use in the Perioperative Patient: A Systematic Review.
Kassel Lynn, Nelson Megan, Shine Jaclyn et al. · AORN J · 2018
PMID: 30156728Meta-Analysis
Scopolamine (hyoscine) for preventing and treating motion sickness.
Spinks Anneliese, Wasiak Jason · Cochrane Database Syst Rev · 2011
PMID: 21678338Meta-AnalysisFull text (PMC)
Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis.
Apfel Christian C, Zhang Kun, George Elizabeth et al. · Clin Ther · 2010
PMID: 21118734Meta-Analysis
Scopolamine (hyoscine) for preventing and treating motion sickness.
Spinks A B, Wasiak J, Villanueva E V et al. · Cochrane Database Syst Rev · 2007
PMID: 17636710Meta-Analysis
Scopolamine for preventing and treating motion sickness.
Spinks A B, Wasiak J, Villanueva E V et al. · Cochrane Database Syst Rev · 2004
PMID: 15266468Meta-Analysis
The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
Kranke Peter, Morin Astrid M, Roewer Norbert et al. · Anesth Analg · 2002
PMID: 12088957Meta-Analysis
Scopolamine's Anticholinergic Effects on EEG Spectral, Aperiodic, Complexity, Microstates, and Heart Rate Variability.
Chen Joseph C C, Sumner Rachael L, Thorstensen Eric B et al. · Hum Psychopharmacol · 2025
PMID: 41122044RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Scopolamine (substance)
SNOMED CT
387409009
UMLS CUI
C0036442
RxNorm CUI
9601
Labeler
Rhodes Pharmaceuticals L.P.

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.